SEARCH WITHIN CONTENT
Citation Information : Immunohematology. Volume 33, Issue 3, Pages 119-124, DOI: https://doi.org/10.21307/immunohematology-2019-018
License : (Transfer of Copyright)
Published Online: 09-October-2019
Molecular genotyping platforms provide a quick, high-throughput method for identifying red blood cell units for patients on extended phenotype-matching protocols, such as those with sickle cell disease or thalassemia. Most of the antigen prevalence data reported are for non-Hispanic populations. Therefore, this study sought to determine the phenotype prevalence in a single blood center’s Hispanic population and to compare those results with previously reported rates in non-Hispanic donor populations. We performed a retrospective review of all serologic and molecular typing from donors who self-reported as Hispanic. The phenotype prevalence was reported and compared with rates from other racial/ethnic groups. A total of 1127 donors who selfidentified as Hispanic were screened by serologic methods for Rh and Kell antigens, and 326 were subsequently selected for molecular typing. The most prevalent probable Rh phenotypes were R1r (26.6%), R1R2 (21.5%), and R1R1 (20.7%); rr was found in 7.8 percent of donors tested. The percentage of K+ donors in this population was 2.8 percent. The most prevalent Duffy phenotypes were Fy(a+b+) (35.9%), Fy(a+b–) (35.6%), and Fy(a–b+) (27%). Of the donors studied, 15.3 percent had an FY GATA mutation. Only 1.5 percent of the donors were Fy(a–b–). The Jk(a+b+) phenotype was found in nearly half of the population. M+N+S+s+ was the most prevalent MNS phenotype from that group, constituting 22.4 percent. A total of 95.7 percent of the donors were Lu(a–b+), and Di(a–b+) was observed in 94.4 percent. The most prevalent Dombrock phenotype was Do(a+b+), constituting 46.9 percent, followed closely by Do(a–b+) at 40.5 percent. Hispanic donor antigen prevalence is distinctly different from other racial/ethnic groups and should be considered when attempting to find extended matched units for these patients.
1. Aranda LI, Smith LA, Jones S, et al. Red cell antigen prevalence predicted by molecular testing in ethnic groups of South Texas blood donors. Immunohematology 2015;31:166–73.
2. Thompson C. Diego(a) antigen frequency and anti-Diego(a) frequency in a South Texas community. Clin Lab Sci 2006;19:203–5.
3. Mallory D, Ed. Immunohematology methods and procedures. 1st ed. Rockville, MD: American Red Cross, 1993.
4. Reid M, Lomas-Francis C, Olsson M. The blood group antigens factsbook. 3rd ed. Oxford, UK: Elsevier/Academic Press, 2012.
5. Wilkinson K, Harris S, Gaur P, et al. Molecular blood typing augments serologic testing and allows for enhanced matching of red blood cells for transfusion in patients with sickle cell disease. Transfusion 2012;52:381–8.
6. Edwards-Moulds JM, Alperin JB. Studies of the Diego blood group in Mexican-Americans. Transfusion 1986;26:234–36.
7. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013;122:1062–71.
8. Hollenbach JA, Saperstein A, Albrecht M, et al. Race, ethnicity and ancestry in unrelated transplant matching for the National Marrow Donor Program: a comparison of multiple forms of self-identification with genetics. PLoS One 2015;10:e0135960.
9. Lee YL, Teitelbaum S, Wolff MS, et al. Comparing genetic ancestry and self-reported race/ethnicity in a multiethnic population in New York City. J Genet 2010;89:417–23.
10. Banda Y, Kvale MN, Hoffmann TJ, et al. Characterizing race/ ethnicity and genetic ancestry for 100,000 subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. Genetics 2015;200:1285–95.
11. KR Humes, NA Jones, RR Ramirez. Overview of race and Hispanic origin: 2010 (Census briefs) March 2011. Pg. 2. Available from www.census.gov/prod/cen2010/briefs/c2010 br-02.pdf.
12. Centers for Disease Control Web site. Last reviewed and updated August 31, 2016. Available from www.cdc.gov/ ncbddd/sicklecell/data.html.
13. Harm SK, Yazer MH, Monis GF, et al. A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol 2014;141:256–61.
14. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41:1086–92.
15. Tahhan HR, Holbrook CT, Braddy LR, et al. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 1994;34:562–9.
16. Casas J, Friedman DF, Jackson T, et al. Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion 2015;55:1388–93.